Novo Drugs Ozempic and Wegovy Are Shaking Up Stock Markets Again
- Kidney-dialysis providers are latest to come under pressure
- Food stocks fell last week on worries over impact on demand
An Ozempic needle injection pen.
Photographer: Jaap Arriens/NurPhoto/Getty Images
This article is for subscribers only.
The disruptive impact on stock markets of Novo Nordisk A/S’s diabetes drugs is getting ever wider.
The Danish company, now Europe’s largest by market value, said late Tuesday it was halting a study which looked at the impact of its blockbuster Ozempic drug on kidney failure after it showed effectiveness surprisingly early.